Co-Diagnostics, Inc. (0A50.L)
LSE · USD
$0.5338 (-5.95%) as of
Key statistics
- P/E (TTM)
- 0.41
- EPS (TTM)
- 1.3120
- 52-week range
- 0.5120 – 2.9780
- Beta
- 2.90
- Revenue (TTM)
- 721.39k
- Profit margin
- 0.00%
- Volume
- 20.98k
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
- Headquarters
- Salt Lake City, UT, United States
- Employees
- 115
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.